About Us

Founded in 2021, RinuaGene is dedicated to developing innovative RNA therapeutics and vaccines to address critical health challenges around the world. With a strong foundation in scientific expertise, pharmaceutical industry experience, and managerial excellence, RinuaGene is efficiently advancing its FIC/BIC product pipeline and strengthening its cutting-edge technological platform. Driven by innovation, RinuaGene is committed to establishing a world-class platform for RNA-based drugs and vaccines. Our goal is to deliver high-quality, transformative solutions that improve human health and contribute to a healthier future worldwide.

Read More

Pipeline

A Promising Pipeline

RinuaGene has established a strong and diversified pipeline with best-in-class or first-in-class potential. The focused areas are immunotherapy, in vivo protein replacement therapy, and prophylactic vaccine.

Read More

Platform

RinuaGene developed an end-to-end RNA R&D and CMC technological platform and quickly turned concepts into products.

Targeted Delivery Precise tissue/cell expression via multidimensional targeted delivery. Read More >
RNA Engineering Enhanced expression, durability and selectivity. Read More >
Robust CMC Efficient, reliable manufacturing at scale. Read More >
Data Science & AI From early discovery to product development. Read More >

News

RinuaGene's HPV Therapeutic mRNA Vaccine Received IND Clearance from China CDE December 04, 2024 CDE officially announced the clinical trial approval for RG002 Injection. Read More Advanced Science | RinuaGene Published Data on Novel mRNA LNP Delivery System October 16, 2024 RinuaGene publishes novel lipid (4S)-KEL12 paper in Advanced Science. Read More Molecular Therapy | RinuaGene Published Early Research Data of HPV Therapeutic Vaccine May 16, 2024 RinuaGene advances HPV mRNA candidate RG002 into the clinical development. Read More
Careers Join us, and grow rapidly with RinuaGene! Read More